Objectives: Intensity-modulated radiation therapy (IMRT) has been shown to decrease abdominal toxicity in patients undergoing chemoradiation (CRT) for pancreatic cancer. We evaluated whether IMRT impacts the rates of hematologic toxicity and chemotherapy dose intensity in patients undergoing CRT.
P
ancreatic cancer is the fourth most common cause of cancer death in the United States. Surgical resection is necessary for cure although only 10% to 20% of tumors are amenable to resection at diagnosis. 1 For patients with unresectable disease, a multimodality approach is commonly used although the median survival is still only 9 to 12 months. 2, 3 Although distant failure is frequent, local failure also plays an important role in these patients. 4 For this reason, both systemic and local therapies are critical in the management of patients with localized pancreatic cancer.
A limitation to radiotherapy for pancreatic cancer has been toxicity related to irradiation to nearby organs. Specifically, radiation treatment volumes may encompass the small bowel or stomach resulting in gastrointestinal morbidity. In addition, due to the proximity of the liver and kidney to the pancreas, these may be limiting structures when treating patients with radiation. Studies have suggested that intensitymodulated radiation therapy (IMRT) may allow for dose reduction to surrounding abdominal structures compared with 3D-conformal radiotherapy (3D-CRT). 5, 6 In addition to gastrointestinal toxicity, hematologic toxicity is commonly seen in patients undergoing gemcitabinebased chemoradiation (CRT). This is primarily due to the myelosuppresion of gemcitabine which can result in significant hematologic toxicities. It is hypothesized that the large amount of thoracolumbar bone marrow irradiation in conventional pancreas radiation portals may also be a significant contributor to hematologic toxicity, due to 20% to 40% of a patient's bone marrow contained within conventional pancreas radiation fields. 7 Hematologic toxicity during CRT may result in the need for growth factors, transfusions, and unnecessary treatment breaks. Ultimately, it is believed that dose reductions in chemotherapy and prolonged radiation treatment courses may affect the efficacy of the treatment. 8 IMRT has been shown to be beneficial in reducing normal organ toxicity in patients undergoing abdominal radiation. We hypothesized that IMRT would reduce the volume of thoracolumbar bone marrow in patients undergoing concurrent CRT and thus reduce hematologic toxicity and improve the ability to deliver chemotherapy.
MATERIALS AND METHODS

Patient Selection
After institutional review board approval, we identified all patients undergoing concurrent CRT at Fox Chase Cancer Center between 2006 and 2012 for borderline resectable or locally advanced pancreatic cancer. Exclusion criteria included receipt of non-gemcitabine therapy, chemotherapy before From the Departments of *Radiation Oncology; wBiostatistics; zMedical Oncology; and ySurgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. Supported by grant number P30 CA006927 from the National Cancer Institute, NIH. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
CRT, or abnormal baseline hematologic indices. Following completion of CRT, all patients were offered post-CRT chemotherapy. Patients who were considered potentially resectable underwent surgical exploration followed by resection after completion of post-CRT chemotherapy. All patients were staged pre-and postoperatively according to the tumor-node-metastasis (TNM) classification of the American Joint Committee for Cancer Staging Version 7. 9 Pretreatment clinical staging routinely included a pancreas protocol computed tomography scan, endoscopic ultrasound, and serum CA 19-9. Histopathologic or cytologic confirmation of diagnosis was established before CRT in all patients. Borderline resectable and locally advanced tumors were defined according to National Comprehensive Cancer Network version 2.2014 guidelines.
Baseline data collected included general patient characteristics (age, sex, diagnosis date, histology) and treatment characteristics (chemotherapy regimen, chemotherapy dose, radiation dose, radiation technique, radiation boost, surgery). Follow-up data were obtained from patient medical records, referring physicians, and telephone interviews.
Treatment
All patients received concurrent radiotherapy with gemcitabine. Gemcitabine typically received during CRT was 600 mg/m 2 /week for a planned total dose of 3600 mg/m 2 during CRT. Patients were typically scheduled to receive 1000 mg/m 2 on days 1, 8, and 15, every 4 weeks post-CRT for a total of 9000 mg/m 2 within the first 3 months of completing CRT. During radiation treatment simulation, patients typically underwent a contrast-enhanced CT with oral and intravenous contrast with immobilization using a custom cast. The majority of patients underwent 4-dimensional CT planning. The treatment volumes generally consisted of the pancreatic mass and grossly involved lymph nodes plus a margin of 1 to 2 cm. Regional lymph nodes were not routinely prophylactically treated. The median radiation dose was 50.4 Gy (range, 45 to 56 Gy) in 25 to 28 fractions. Daily cone beam computed tomography scan was used for localization. For patients being treated with IMRT, inverse treatment planning was used with 7 to 9 coplanar fields or using volumetric modulated arc therapy with 1 to 3 complete or partial arcs. The goal was for 95% of the planning target volume to receive the prescription dose. For patients being treated with 3D-CRT, treatment generally consisted of a 4-field technique consisting of an AP/PA and 2 lateral fields. The majority of patients were treated with 3D-CRT until 2008, after which all patients were treated with IMRT.
Statistical Analysis
Endpoints evaluated included total gemcitabine dose received during CRT and within 3 months of CRT completion, dose intensity during CRT and within 3 months of CRT completion, unplanned dose reduction, and hematologic toxicity (WBC, ANC, platelets, and hemoglobin). The dose intensity represented the ratio of the actual dose intensity over the planned dose intensity. Hematologic toxicity was identified during CRT and 3 months following completion of CRT. The lowest level of each hematologic variable during CRT and post-CRT, respectively, was designated as the nadir. Hematologic toxicity was defined as grade 3 + hematologic toxicity per Common Terminology Criteria for Adverse Events (CTCAE) 4.0. The Fisher exact test and regression models were used to test the correlation between IMRT and 3D-CRT with clinical and treatment variables. Because of the multiple comparisons in the presented analysis, a false discovery rate (FDR) adjustment was performed at the 5% FDR level.
RESULTS
A total of 85 patients met the inclusion criteria with a median age of 69 years (range, 44 to 81 y) and a median follow-up of 13.2 months (range, 3 to 68 mo). The majority of patients were male (46, 54.1%). Most patients had either clinical T3 (38, 44.7%) or N0 (54, 63.5%) disease. A total of 71 (83.5%) patients received post-CRT chemotherapy and 26 (30.5%) patients underwent surgical resection. A total of 58 (68.2%) patients received treatment with IMRT, and 27 (31.8%) patients were treated with 3D-CRT. The majority of patients had pancreatic head tumors in both groups (89.7% IMRT vs. 96.3% 3D-CRT, P = 0.45) and a similar number of patients went on to surgical resection (31% IMRT vs. 29.6% 3D-CRT, P = 0.9). There was no significant difference between the groups in terms of clinical characteristics. Patient characteristics are further demonstrated in Table 1 .
Chemotherapy Dose
The median chemotherapy dose received during CRT was 3000 mg/m 2 of a planned 3600 mg/m 2 and post-CRT was 5000 mg/m 2 of a planned 9000 mg/m 2 . During CRT, 19 (22.3%) patients had a dose reduction, 5 (5.9%) patients had a dose held during CRT, and 2 (2.4%) patients had both.
During CRT, there was no relationship between treatment technique and total dose of gemcitabine received (P = 0.88) or dose intensity (P = 0.88) (Fig. 1 ). There was a trend toward increased dose reduction in patients receiving IMRT (P = 0.06). In the first 3 months post-CRT, there was also no relationship between treatment technique and total dose of gemcitabine received (P = 0.66), dose intensity (P = 0.72) or dose reduction (P = 0.91) (Fig. 1) .
When examining other factors correlated with chemotherapy use, patients receiving a higher percentage of the intended chemotherapy dose during CRT received a lower percentage of desired chemotherapy dose post-CRT (P = 0.007), although this was no longer significant after applying the FDR.
Patients undergoing surgical resection (P < 0.01) and receiving a higher radiation dose (P = 0.03) were more likely to receive a higher total post-CRT dose although this was also no longer significant after applying the FDR. There were no variables correlated to chemotherapy dose received during CRT.
Hematologic Toxicity
During CRT, the median WBC was 2.4 (0.9 to 11), the median ANC was 1.45 (0.5 to 10.8), the median hemoglobin was 10.4 (1.2 to 13.8), and the median platelets were 107 (23 to 289). The rates of hematologic grade 3 + toxicity during and after CRT are further demonstrated in Figure 2 .
When examining by type of radiation treatment technique, during CRT there was no correlation with WBC (P = 1.00), ANC (P = 0.16), hemoglobin (P = 1.00), or platelet (P = 1.00) grade 3 + toxicity. The frequency of grade 3 + hematologic toxicity during CRT is listed in Table 2 . When examining these hematologic covariates as continuous variables, these remained nonsignificant. In the first 3 months after CRT, patients receiving IMRT were more likely to have ANC grade 3 + toxicity (P < 0.01). Otherwise there was no relationship between treatment technique and WBC (P = 0.49), hemoglobin (P = 0.27), or platelet (P = 0.73) grade 3 + toxicity. The frequency of grade 3 + hematologic toxicity within 3 months of completing CRT is listed in Table 3 . When examining these hematologic covariates as continuous variables, there was no relationship with treatment technique.
When examining other factors correlated with hematologic toxicity during CRT, total chemotherapy dose received was a significant predictor for WBC (P = 0.02), ANC (P = 0.03), and hemoglobin (P < 0.01) grade 3 + toxicity although there was no correlation with platelet toxicity (P = 0.15). The only other factor correlated with hemoglobin grade 3 + toxicity was age (P < 0.01). There were no other factors related to hematologic toxicity. Following the completion of CRT, total chemotherapy dose was a predictor of WBC (P = 0.04) and ANC (P = 0.19) grade 3 + toxicity. The only other factor correlated with grade 3 + post-CRT ANC toxicity was surgery (P < 0.01). Otherwise there were no other factors related to post-CRT hematologic toxicity.
DISCUSSION
Systemic therapy plays an important role in the management of patients with pancreatic cancer due to the high likelihood of distant failure. We evaluated whether the use of IMRT in patients with borderline resectable or locally advanced pancreatic cancer impacts the receipt of gemcitabine-based chemotherapy. In addition, as hematologic toxicity is a common limiting factor in patients undergoing CRT for pancreatic cancer, we evaluated whether IMRT reduces the risk of hematologic toxicity in patients receiving concurrent CRT. Overall, we found no difference in chemotherapy dose received during CRT in patients receiving IMRT versus 3D-CRT although there was a trend toward increased dose reductions in patients receiving IMRT-based treatment. There was no difference in hematologic toxicity when evaluating these 2 subgroups. When examining chemotherapy toxicity post-CRT, there was a higher rate of ANC toxicity in patients undergoing IMRT although this was no longer significant after applying a FDR of 5%. There was no association between radiation treatment technique and lower chemotherapy dose received or increased dose reductions.
IMRT has been increasingly adopted in the management of a variety of malignancies due to the ability to achieve conformality while reducing the dose to critical structures. A disadvantage of IMRT is the higher incidence of low-dose spread to achieve these more conformal plans. Historically, radiation fields for patients undergoing pancreatic radiation have been large and have resulted in significant morbidity. The most dose-limiting structure in pancreatic radiation fields is typically the small bowel. Acute toxicity is often caused by damage to epithelial cells and may result in diarrhea or bleeding which is often potentiated by systemic therapy. Late toxicity may be in the form of obstruction or strictures requiring a need for surgical intervention.
Because of the location of the pancreas, IMRT is particularly intriguing due to the surrounding critical structures and the inability to deliver adequate dose without increasing toxicity. Yovino et al 10 examined a cohort of patients undergoing concurrent chemotherapy and IMRT-based radiotherapy for pancreatic and ampullary cancers. When compared with historical controls, IMRT resulted in a statistically significant decrease in grade 3 to 4 nausea/vomiting and diarrhea. Abelson and colleagues demonstrated a similar subset of patients undergoing CRT with 5-FU-based therapy. In their analysis, only 9% of patients experienced grade 3 + gastrointestinal toxicity with a 64% locoregional control rate. 11 Other trials have also demonstrated the feasibility of IMRT in treating pancreatic cancer. [12] [13] [14] In our current study, 12% of patients experienced grade 3 + hematologic toxicity. The toxicity results presented in our analysis are consistent with large phase III randomized trials in this cohort of patients. All patients enrolled in RTOG 97-04 were treated using 3D-CRT with 58% of patients in the gemcitabine arm experiencing grade 3 + hematologic toxicity versus 9% in the 5-FU arm. 15 In the ECOG E4201 trial comparing gemcitabine alone versus CRT with gemcitabine, the incidence of hematologic toxicity was greater in the CRT arm. 16 Overall, the grade 3 + hemoglobin, leukocyte, lymphocyte, neutrophil, and platelet toxicities were 17.6%, 32.4%, 2.9%, 38.2%, and 20.6%, respectively. These hematologic toxicities ultimately did not result in a chemotherapy dose deintensification in the CRT arm. Similarly, in the French federation trial, comparing CRT with 5-FU versus gemcitabine alone in patients with locally advanced disease, the hematologic toxicity was greater in the CRT arm with 70.7% of patients experiencing grade 3 + toxicity versus 26.7% with gemcitabine alone. Although the most common side effects of abdominal radiation are typically gastrointestinal, it is evident that radiation may increase hematologic toxicity.
In other disease sites, bone marrow sparing treatment using IMRT has been found to reduce hematologic toxicity. Brixey et al 17 examined the impact of IMRT on hematologic toxicity in patients being treated for gynecologic malignancies. In their analysis, the use of IMRT resulted in reduced hematologic toxicity and less bone marrow irradiated. Mell et al 18 examined patients with cervical cancer being treated (23) 10 (14) CRT indicates chemoradiation; IMRT, intensity-modulated radiation therapy.
with IMRT versus conventional AP-PA and 4-field box plans. In their analysis, IMRT reduced the pelvic bone marrow dose versus AP-PA plans and reduced the lumbosacral dose versus 4-field plans. Similarly, when examining a cohort of patients with anal carcinoma, Mell et al 19 found that increased pelvic bone marrow dose and lumbosacral bone marrow dose resulted in decreased WBC and ANC nadirs. Hui et al 20 demonstrated that IMRT reduced bone volume irradiation and subsequent acute hematologic toxicity. Multiple other series have demonstrated a correlation between bone marrow irradiation and hematologic toxicity. [21] [22] [23] Identifying means to minimize bone marrow irradiation may reduce further hematologic toxicity.
In our analysis, IMRT use was associated with decreased post-CRT ANC levels without an impact on CRT ANC. Lhomme et al 3 found a correlation between higher rates of hematologic toxicity in patients receiving irinotecan with prior whole pelvis radiation for cervical cancer versus patients with no prior whole pelvis radiation. They concluded that patients with prior pelvic irradiation should have a dose reduction to minimize toxicity. Our analysis demonstrated that patients receiving prior IMRT may have higher post-CRT hematologic complications. These findings indicate that prior radiation to the bone marrow may impact subsequent chemotherapy and should be a consideration when planning treatment fields. Minimizing dose to the pelvic and lumbosacral bone marrow may be a consideration when treating patients with pelvic or abdominal malignancies who are scheduled to receive future myelosuppressive chemotherapy.
Our analysis also demonstrated a higher total post-CRT dose received in patients undergoing surgical resection and receiving higher radiation doses. This correlation is not surprising; patients who are considered fit may receive more intensive therapy versus poor performance status patients. Similarly, patients undergoing surgical resection had higher rates of grade 3 + post-CRT ANC toxicity likely representing the dose intensification often attempted in these patients.
To our knowledge, this is the first report demonstrating increased hematologic toxicity in patients receiving IMRT for pancreatic cancer. We hypothesized that the use of IMRT would result in a decrease in the amount of bone marrow irradiated, minimizing hematologic toxicity and dose reductions. IMRT has been successfully used in many other disease sites to spare toxicity. 24, 25 In our subset of patients, there was a suggestion that IMRT may result in an increased rate of ANC toxicity post-CRT, contrary to our hypothesis. Although IMRT is often used to reduce dose to organs at risk, the low-dose spread has been implicated as a limiting treatment factor. For example, the V5 (volume receiving 5 Gy) in patients undergoing lung radiotherapy has been a strong predictor of radiation pneumonitis in patients undergoing concurrent CRT for lung malignancies. 26 We believe that low-dose spread to the bone marrow may result in increased hematologic toxicity in patients undergoing radiotherapy using IMRT. Interestingly, there was no impact on hematologic toxicity during CRT.
Limitations of our analysis include those inherent to retrospective reviews. In addition, although we limited analysis to patients with normal baseline hematologic indices, this does not eliminate the likelihood of borderline low hematologic variables or undetected bone marrow suppression. We did exclude patients not receiving neoadjuvant chemotherapy to allow for a more homogenous cohort. In addition, performance status was not controlled in the above study. As a result, patients who may have multiple comorbidities or other factors impacting their ability to receive chemotherapy were not corrected for and may convolute our findings.
Our analysis indicates that IMRT may result in increased hematologic toxicity in patients undergoing CRT although this did not result in an alteration in chemotherapy dose received. Although the clear etiology of this is uncertain, we hypothesize that bone marrow irradiation may have resulted in increased bone marrow ablation. By minimizing the myelosuppression secondary to radiation, this may allow for increased dose intensity. This is particularly important due to the increasing utilization of combination CRT regimens in the management of this cohort of patients. Future studies are indicated to better establish the role of bone marrow sparing radiation.
